FY2025 EPS Forecast for ProQR Therapeutics Cut by Analyst

ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of ProQR Therapeutics in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the biopharmaceutical company will earn ($0.43) per share for the year, down from their prior estimate of ($0.39). Cantor Fitzgerald has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

Other analysts have also recently issued reports about the company. Oppenheimer dropped their price target on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a report on Tuesday. Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price on the stock in a research report on Monday, March 10th. Evercore ISI initiated coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price target for the company. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday, March 14th. Finally, HC Wainwright boosted their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ProQR Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $8.00.

ProQR Therapeutics Stock Down 3.8%

Shares of PRQR stock opened at $1.53 on Wednesday. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.62. The company has a market capitalization of $160.98 million, a PE ratio of -4.78 and a beta of 0.35. The firm has a 50 day moving average price of $1.48 and a two-hundred day moving average price of $2.37.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $4.90 million.

Hedge Funds Weigh In On ProQR Therapeutics

A number of institutional investors have recently modified their holdings of the business. Ballentine Partners LLC bought a new stake in shares of ProQR Therapeutics during the 4th quarter valued at approximately $61,000. M&T Bank Corp acquired a new stake in shares of ProQR Therapeutics during the fourth quarter valued at about $330,000. Raymond James Financial Inc. bought a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $260,000. PNC Financial Services Group Inc. bought a new position in ProQR Therapeutics in the 4th quarter valued at approximately $77,000. Finally, Platinum Investment Management Ltd. bought a new stake in ProQR Therapeutics during the 4th quarter worth approximately $4,076,000. Institutional investors and hedge funds own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.